One new responder observed in the [ 212 Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated...
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development...
Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability Three clinical-stage oncology programs advancing across neuroendocrine...
Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...
Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...
Barchart Research What to Expect from CATX Earnings CATX Generated May 8, 2026 Current Price $3.76 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 4.60% Perspective Therapeutics Reports Another...
SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced...
Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025 Safety update presented on all 64 patients who...
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced...
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced...